AR041243A1 - Vacuna para ostertagia - Google Patents

Vacuna para ostertagia

Info

Publication number
AR041243A1
AR041243A1 ARP030103307A ARP030103307A AR041243A1 AR 041243 A1 AR041243 A1 AR 041243A1 AR P030103307 A ARP030103307 A AR P030103307A AR P030103307 A ARP030103307 A AR P030103307A AR 041243 A1 AR041243 A1 AR 041243A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
proteins
parts
refers
acid sequences
Prior art date
Application number
ARP030103307A
Other languages
English (en)
Inventor
Peter Geldhof
Isabel Vercauteren
Edwin Claerebout
Jozef Vercruysse
Maere Veerle De
Original Assignee
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gent filed Critical Univ Gent
Publication of AR041243A1 publication Critical patent/AR041243A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a secuencias de ácidos nucleicos que codifican a proteínas de Ostertagia ostertagi y a partes de tales secuencias de ácidos nucleicos que codifican a un fragmento inmunogénico de tales proteínas, y a fragmentos de ADN,moléculas de ADN recombinantes, portadores recombinantes vivos y células huésped que comprenden a tales secuencias de ácidos nucleicos o tales partes de las mismas. La presente también se refiere a proteínas de Ostertagia ostertagi y a partesinmunogénicas de las mismas codificadas por tales secuencias. Además, la presente se refiere a vacunas que comprenden tales secuencias de ácidos nucleicos y a partes de las mismas, fragmentos de ADN, moléculas de ADN recombinante, portadoresrecombinantes vivos y células huésped que comprenden a tales secuencias de ácidos nucleicos o tales partes de las mismas, proteínas o partes inmunogénicas de las mismas y anticuerpos contra tales proteínas o partes inmunogénicas de las mismas.Además, la presente se refiere al uso de dichas proteínas en vacunas y para la elaboración de vacunas. Además, la presente se refiere al uso de dichas secuencias de ácidos nucleicos, proteínas o anticuerpos para propósitos de diagnóstico o devacunación. Finalmente, la presente se refiere a kits de diagnóstico que comprenden a tales ácidos nucleicos, proteínas o anticuerpos contra tales proteínas. Reivindicación 1: Secuencia de ácidos nucleicos que codifica a una proteína de Ostertagiaostertagi o una parte de dicha secuencia de ácidos nucleicos que codifica a un fragmento inmunogénico de dicha proteína, teniendo secuencia de ácidos nucleicos o dicha parte de la misma por lo menos 85%, preferentemente 90, más preferentemente 95%de homología con la secuencia de ácidos nucleicos del gen de la proteína de Ostertagia ostertagi como se ilustra en la SEQ ID NO: 7.
ARP030103307A 2002-09-13 2003-09-12 Vacuna para ostertagia AR041243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/243,319 US20040052817A1 (en) 2002-09-13 2002-09-13 Ostertagia vaccine

Publications (1)

Publication Number Publication Date
AR041243A1 true AR041243A1 (es) 2005-05-11

Family

ID=31991608

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103307A AR041243A1 (es) 2002-09-13 2003-09-12 Vacuna para ostertagia

Country Status (11)

Country Link
US (4) US20040052817A1 (es)
EP (1) EP1539820B1 (es)
AR (1) AR041243A1 (es)
AT (1) ATE392435T1 (es)
AU (1) AU2003270190B2 (es)
BR (2) BR0314258A (es)
CA (1) CA2498249C (es)
DE (1) DE60320425T2 (es)
ES (1) ES2304526T3 (es)
NZ (1) NZ542733A (es)
WO (1) WO2004024769A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052817A1 (en) * 2002-09-13 2004-03-18 Peter Geldhof Ostertagia vaccine
BR0314273A (pt) * 2002-09-13 2005-07-19 Ovita Ltd Inibidor de protease de aspartil como um alérgeno de nematódeo
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB894603A (en) * 1959-09-02 1962-04-26 Allen & Hanburys Ltd Improvements in or relating to vaccines
AU7734994A (en) 1993-09-28 1995-04-18 Meat Research Corporation Protective antigens against parasites
US5753787A (en) * 1995-04-10 1998-05-19 Yale University Nucleic acids encoding ancylostoma secreted protein
US5759782A (en) * 1995-06-07 1998-06-02 The United States Of America Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US6017757A (en) * 1997-02-20 2000-01-25 Mississippi State University Isolated viable nematode intestinal cells
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US20040052817A1 (en) * 2002-09-13 2004-03-18 Peter Geldhof Ostertagia vaccine

Also Published As

Publication number Publication date
US20100209446A1 (en) 2010-08-19
US20050271683A1 (en) 2005-12-08
AU2003270190B2 (en) 2008-09-04
EP1539820B1 (en) 2008-04-16
DE60320425T2 (de) 2008-07-31
CA2498249C (en) 2016-09-06
NZ542733A (en) 2007-06-29
US20090028892A1 (en) 2009-01-29
US7718179B2 (en) 2010-05-18
WO2004024769A2 (en) 2004-03-25
ES2304526T3 (es) 2008-10-16
CA2498249A1 (en) 2004-03-25
EP1539820A2 (en) 2005-06-15
US7264812B2 (en) 2007-09-04
BRPI0314258B1 (pt) 2019-07-09
BR0314258A (pt) 2005-07-26
WO2004024769A3 (en) 2004-06-03
ATE392435T1 (de) 2008-05-15
DE60320425D1 (de) 2008-05-29
US20040052817A1 (en) 2004-03-18
US8227584B2 (en) 2012-07-24
AU2003270190A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
ES2545886T3 (es) Inmunoterapia dirigida a patógenos intracelulares
DE69739515D1 (de) Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
CA2408328A1 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
EA201071323A1 (ru) Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения
MXPA06008217A (es) Vacunas con subunidad de lawsonia intracellularis.
NZ735684A (en) Materials and methods for respiratory disease control in canines
HUP0105379A2 (hu) Lawsonia intracellularis elleni oltóanyag
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
NZ598605A (en) Vaccine against african horse sickness virus
AR015252A1 (es) Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo
AR036793A1 (es) Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante
WO2003095480A3 (en) Brachyspira hyodysenteriae vaccine
AR041243A1 (es) Vacuna para ostertagia
ZA200602107B (en) Piroplasmid vaccine
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
AR040830A1 (es) Vacuna para combatir la infeccion que produce la mastitis
NO20081541L (no) Ny sjo-lus vaksine
PL1962889T3 (pl) Immunogenny polipeptyd złożony z optymalizowanych kryptycznych peptydów wyprowadzonych z antygenu nowotworu oraz jego zastosowania
AR019864A1 (es) Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry
WO2004007726A3 (en) Brachyspira hyodysenteriae vaccine
CU23245A1 (es) CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
BRPI0412419A (pt) proteìna de babésia, ácido nucleico, fragmento de cdna, molécula de dna recombinante, veìculo recombinante vivo, célula hospedeira, vacina, método para a preparação de uma vacina, uso de uma proteìna ou um fragmento imunogênico de referida proteìna, e, testes diagnósticos para a detecção de um ácido nucleico associado com, para a detecção de anticorpos contra, e para a detecção de material antigênico de um organismo da famìlia babesiidae
DE50106199D1 (de) Regulatorische sequenz zur spezifischen expression in dendritischen zellen und deren anwendungen
BRPI0417440A (pt) ácido nucleico, fragmento e molécula de dna, veìculo recombinante vivo, célula hospedeira, proteìna de lawsonia intracellularis, vacina para combater as infecções com lawsonia intracelularis, método para a preparação de uma vacina, e, testes de diagnóstico para aldetecção de anticorpos contra lawsonia intracellularis e material antigênico de lawsonia intracellularis
HUP0200832A2 (hu) Babesia canis oltóanyag

Legal Events

Date Code Title Description
FC Refusal